Alexandria Real Estate Equities, Inc. (ARE)
Alexandria Real Estate Equities is a specialist landlord that builds and manages high-tech office and laboratory spaces for the life science and technology sectors.
Is Alexandria Real Estate Equities, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Specialised focus on high-demand life science infrastructure. Worth weighing: Recent decline in revenue growth. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Alexandria Real Estate Equities, Inc. actually fallen?
Over the last 2 years of daily prices, Alexandria Real Estate Equities, Inc. fell as much as −68% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
The company successfully pivots to become the dominant landlord for the next generation of medical research.
Structural changes in how research is conducted lead to a permanent decline in office-based lab demand.
What does Alexandria Real Estate Equities, Inc. do?
Think of this company as a landlord for scientists; they own the specialised buildings where pharmaceutical and biotech firms conduct their research. The company collects rent from these tenants, who often sign long-term leases. Filling their buildings is the challenge, since demand for high-end lab space is going through a bit of a cooling-off period.
On our factor screen it looks strongest on value and income, and weakest on growth.
- ✓Pays a dividend - about 5.6% a year
- !Revenue slipped about 12% over the year
- Specialised focus on high-demand life science infrastructure
- High gross margins suggest efficient property management
- Attractive dividend yield for income-focused observers
- Growth screens low (2/100)
- High sensitivity to interest rate fluctuations
- Concentration risk in the biotech and pharmaceutical sectors
- Potential for further asset devaluation in a tough property market
What do Alexandria Real Estate Equities, Inc.'s numbers mean?
How much money does Alexandria Real Estate Equities, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Alexandria Real Estate Equities, Inc. pay a dividend?
Yes - Alexandria Real Estate Equities, Inc. currently pays a dividend of about 5.6% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
What do the numbers say about Alexandria Real Estate Equities, Inc.'s dividend?
There's no rating here, and we don't judge whether the dividend will continue - that would be advice. Here are the figures income investors usually look at, and what each one means, so you can weigh it up yourself.
Figures are from the latest available data and can be distorted by one-off results. Past payments don't predict future ones, and a dividend can be cut at any time. This lays out the numbers to help you understand them - it is not a view on what will happen.
When does Alexandria Real Estate Equities, Inc. report earnings, and how did recent quarters go?
Alexandria Real Estate Equities, Inc. is next scheduled to report on about 2026-08-03 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-04-27 | $0.14 | $2.10 | Beat +1360% |
| 2026-01-26 | $0.30 | $-6.35 | Missed -2201% |
| 2025-10-27 | $0.39 | $0.50 | Beat +28% |
| 2025-07-21 | $0.63 | $0.48 | Missed -24% |
| 2025-04-28 | $0.60 | $0.51 | Missed -16% |
| 2025-01-27 | $0.90 | $0.69 | Missed -23% |
Across the last 6 quarters here, Alexandria Real Estate Equities, Inc. came in ahead of what analysts expected 2 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Real Estate
Simon Property Group, Inc.
Federal Realty Investment Trust
Host Hotels & Resorts, Inc.
VICI Properties Inc.
Iron Mountain Incorporated
Healthpeak Properties, Inc.
Regency Centers Corporation
Welltower Inc.What are the scenarios for Alexandria Real Estate Equities, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Alexandria Real Estate Equities, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Specialised focus on high-demand life science infrastructure
- High gross margins suggest efficient property management
- Attractive dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone. for income-focused observers
- Recent decline in revenue growth: How fast the company's sales grew versus a year ago.
- Negative net margins indicate current profitability challenges
- Share price has seen significant downward pressure over the last year
- High sensitivity to interest rate fluctuations
- Concentration risk in the biotech and pharmaceutical sectors
- Potential for further asset devaluation in a tough property market
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained return to positive net profit margins
- A significant increase in occupancy rates across their portfolio
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.